<- Go Home
Liminatus Pharma, Inc.
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Market Cap
$9.2M
Volume
718.2K
Cash and Equivalents
$337.7K
EBITDA
-$3.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$33.66
52 Week Low
$0.16
Dividend
N/A
Price / Book Value
-0.56
Price / Earnings
-0.48
Price / Tangible Book Value
-0.56
Enterprise Value
$10.3M
Enterprise Value / EBITDA
-3.47
Operating Income
-$3.0M
Return on Equity
70.02%
Return on Assets
-62.65
Cash and Short Term Investments
$337.7K
Debt
$1.4M
Equity
-$9.8M
Revenue
N/A
Unlevered FCF
$7.3M
Sector
Biotechnology
Category
N/A